林业发展局关于Novavax公司进行更多试验的请求引发了疫苗更新和获取方面的不确定性。 FDA's request for additional trial from Novavax sparks uncertainty over vaccine updates and access.

美国食品和药物管理局要求Novavax在获得全面批准后对其COVID-19疫苗进行新的临床试验,这引发了对其他疫苗未来更新的不确定性. The FDA's request for Novavax to conduct a new clinical trial for its COVID-19 vaccine after full approval has sparked uncertainty about future updates to other vaccines. 这一举动可能会拖延每年的紧张情况更新,并对疫苗制造者提出更严格的要求,从而可能影响供应和病人的获得。 This move could delay yearly strain updates and impose stricter requirements on vaccine makers, potentially affecting supply and patient access. 林业发展局决定暂停Novavax的核准程序,引起了人们对制药商或病人可能采取法律行动的关切。 The FDA's decision to pause Novavax's approval process has raised concerns about potential legal action from drugmakers or patients.